microRNA-126 protects ECs from EndMT downstream of ERG and FLI1.

(A) ChIP-seq profiles of ERG, FLI1, and indicated histone modifications (siControl vs siERG+siFLI1) around EGFL7/microRNA-126 loci in HUVECs. (B) Relative expression of microRNA-126-3p quantified by qPCR in HUVECs treated with siERG, siFLI1, or both for 3 days. Data are represented as mean ± SEM (n = 3). *P P t-test. (C) Relative expression of endothelial/mesenchymal markers quantified by qPCR upon restoration of miR-126. HUVECs were treated with siControl+miR-Control (miR-C), siERG+siFLI1+miR-Control or siERG+siFLI1+miR-126 mimic for 3 days. Data are represented as mean ± SEM (n = 3). *P P t-test. NS, not significant. (D) Flow cytometry analysis of endothelial/mesenchymal marker expression. HUVECs were treated with siControl+miR-Control, siERG+siFLI1+miR-Control or siERG+siFLI1+miR-126 mimic for 7 days. See also S10 Fig.